Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting.

Elahere (mirvetuximab soravtansine-gynx) - AbbVie

http://www.ncbi.nlm.nih.gov/pubmed/42733650

Anna V Jones; Brooke E Sanders; Dong Wang; L Stewart Massad; Mary M Mullen; Rachel L Furuya

Sep 15, 2026